NCT07695207 Neovascular Age-Related Macular Degeneration Neovascular Age-Related Macular De… Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07695207—Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07695207 is a hot trial to watch
Neovascular Age-Related Macular Degeneration is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07695207 is notable because it tests Neovascular Age-Related Macular Degeneration in a Phase 3 design with Best corrected visual acuity (BCVA) at Month 12 as a primary decision variable. The wider PatSnap topic query returned 272 trial records and 921 result records, so differentiation depends on evidence quality rather than activity alone.
PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07695207 |
| Official title | Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy |
| Phase / status | Phase 3 / Recruiting |
| Intervention | Not reported |
| Sponsor | Sangmyung University |
| Geography | South Korea |
| Enrollment | 266 |
| Primary endpoint | Best corrected visual acuity (BCVA) at Month 12 |
| Endpoint time frame | Month 12 |
| Primary completion | 2027-12-01 |
| Study completion | 2028-07-01 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Best corrected visual acuity (BCVA) at Month 12—determines what uncertainty this study can resolve. The reported time frame is Month 12. Enrollment of 266 participants and geography in South Korea shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
Benchmark readouts in the same clinical field
- Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT (Phase 3): BCVA(Mean) = 63.0 letters (Standard Deviation, 13.5); BCVA(Mean) = 66.2 letters (Standard Deviation, 12.6); -; -; -.
- Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results (Phase 1): Supplemental anti-VEGF injections(1 year) = 91.7 % .
- A Study in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration to Evaluate a High Dose Aflibercept (8 mg) Prefilled Syringe (Phase 3): Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS = 35 injections ; -; -.
These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: No normalized Drug & Asset record was available for the indexed intervention..
Company & Deal Intelligence context: Sangmyung University — http://www.smu.ac.kr.
The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: randomized data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
NCT07695207 is a focused lens on Neovascular Age-Related Macular Degeneration development. Its value will be determined by whether Neovascular Age-Related Macular Degeneration can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
